Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Neurodegenerative Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
The global market for Neurodegenerative Drugs was valued at US$43.7 Billion in 2024 and is projected to reach US$64.9 Billion by 2030, growing at a CAGR of 6.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Neurodegenerative Drugs market. 
Global Neurodegenerative Drugs Market - Key Trends & Drivers Summarized
Why Is Drug Development for Neurodegenerative Diseases Receiving Renewed Clinical and Commercial Focus?
Neurodegenerative diseases - such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and multiple system atrophy - represent one of the most urgent and complex challenges in global medicine. These disorders involve progressive neuronal degradation, resulting in cognitive, motor, and behavioral impairments that worsen over time and remain largely incurable. As aging populations rise globally, the incidence of these conditions is increasing dramatically, placing immense pressure on healthcare systems and caregivers. Consequently, the market for neurodegenerative drugs is witnessing a surge in interest from pharmaceutical companies, biotech firms, and public health institutions.
Historically, the drug pipeline for neurodegenerative disorders has been plagued by high attrition rates, limited efficacy, and safety concerns. However, breakthroughs in genetics, protein misfolding research, and neuroimmunology are now driving the development of disease-modifying therapies (DMTs) that target underlying pathophysiology rather than just symptomatic relief. Government incentives, fast-track designations, and public-private research initiatives are creating a favorable ecosystem for innovation. As the societal and economic burden of neurodegeneration escalates, drug developers are prioritizing this therapeutic area not only for its medical importance but also for its massive unmet market potential.
How Are Disease-Modifying Approaches and Novel Mechanisms Shaping the Future of Neurodegenerative Drug Therapies?
Recent advances in disease biology have shifted the focus of drug development from symptomatic management to disease-modifying interventions. For Alzheimer's, monoclonal antibodies targeting beta-amyloid (e.g., aducanumab, lecanemab) and tau proteins are under clinical evaluation and conditional approvals. In Parkinson's disease, alpha-synuclein-targeting immunotherapies, LRRK2 inhibitors, and dopamine receptor agonists are being studied to slow dopaminergic neuronal loss. Gene therapies, RNA-targeting drugs (like antisense oligonucleotides), and neurotrophic factor modulators are also being trialed across multiple conditions.
Small molecules targeting neuroinflammation, mitochondrial dysfunction, protein aggregation, and oxidative stress are expanding the scope of therapeutic mechanisms. Additionally, repurposed agents from oncology and immunology are entering late-stage trials in neurodegenerative settings. Biomarker-driven patient selection, digital phenotyping, and the use of fluid biomarkers (such as CSF neurofilament light chain) are improving trial efficiency and therapeutic personalization. These innovations mark a critical transition from palliation to potential alteration of disease trajectory, setting a new precedent for treatment expectations and regulatory pathways.
Which Patient Segments and Global Regions Are Driving Demand for Neurodegenerative Drugs?
The primary patient demographics for neurodegenerative drugs are older adults, especially those over 65, who represent the most affected cohort for Alzheimer's and Parkinson's. Early-onset and genetically predisposed populations are also being identified and monitored more closely through genomic screening, enabling earlier intervention strategies. The increasing diagnosis of mild cognitive impairment (MCI) and prodromal Parkinson's is expanding the treatment window and driving demand for early-stage therapeutics.
Geographically, North America dominates the neurodegenerative drug market due to robust R&D infrastructure, high diagnostic penetration, and early adoption of novel therapeutics. Europe follows with strong regulatory support for rare neurodegenerative conditions and coordinated dementia care initiatives. Asia-Pacific is emerging as a growth frontier, particularly in Japan and China, where rapidly aging populations and increasing investment in neurological research are accelerating demand. Global awareness campaigns, caregiver support programs, and telemedicine expansion are facilitating access and adherence, especially in under-resourced regions.
What Is Fueling Long-Term Growth and Innovation in the Neurodegenerative Drugs Market?
The growth in the neurodegenerative drugs market is driven by demographic trends, advances in neuroscience, and increasing public and private investment in brain health. Aging societies are catalyzing funding for early intervention strategies and long-term disease management solutions. Regulatory bodies are offering accelerated review pathways, conditional approvals, and orphan drug incentives to encourage therapeutic innovation in high-risk, high-failure domains. Meanwhile, venture capital and big pharma partnerships are funneling resources into neurology startups with novel mechanisms of action.
Digital biomarkers, AI-assisted drug discovery, and patient stratification tools are improving trial outcomes and enabling precision neurotherapeutics. Real-world evidence (RWE) and post-market surveillance are being used to support regulatory decisions and inform reimbursement strategies. As the societal toll of neurodegeneration intensifies, therapeutic approaches are expanding to include combination regimens, neurorestorative strategies, and non-invasive neuromodulation. Collectively, these factors ensure that neurodegenerative drugs will remain at the forefront of innovation, investment, and healthcare transformation in the coming decades.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Dopamine Agonist segment, which is expected to reach US$25.7 Billion by 2030 with a CAGR of a 8.3%. The Decarboxylase Inhibitors segment is also set to grow at 7.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $11.9 Billion in 2024, and China, forecasted to grow at an impressive 10.9% CAGR to reach $13.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc., AC Immune SA, Acorda Therapeutics, Inc., Alector, Inc., Alnylam Pharmaceuticals, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 376 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $43.7 Billion |
| Forecasted Market Value (USD) by 2030 | $64.9 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Neurodegenerative Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
FOCUS ON SELECT PLAYERS
- AbbVie Inc.
- AC Immune SA
- Acorda Therapeutics, Inc.
- Alector, Inc.
- Alnylam Pharmaceuticals, Inc.
- Amylyx Pharmaceuticals, Inc.
- Biogen Inc.
- Boehringer Ingelheim GmbH
- CervoMed Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Genentech, Inc.
- H. Lundbeck A/S
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/w610gv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
